Zacks Investment Research on MSN
Why Merck's 32% rally isn't enough to change the bearish view
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...
Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.
5d
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Financial Guidance As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond ...
The Daily Overview on MSN
Eli Lilly closes in on a deal to buy biotech Ventyx
Eli Lilly is moving to deepen its bet on inflammatory disease, striking a deal to acquire biotech player Ventyx Biosciences ...
The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. This report tracks developments currently taking place ...
Republicans are right to offer their own reform alternative to Democrats’ misguided effort to extend ObamaCare’s Covid-era enhanced subsidies (“The GOP’s Better Healthcare Ideas,” Review & Outlook, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback